(MedPage Today) — The FDA approved oral semaglutide (Rybelsus) to prevent major adverse cardiovascular events (MACE) in high-risk patients with diabetes, whether or not they’ve had such an event already, Novo Nordisk announced.
Semaglutide 7…
Source link : https://www.medpagetoday.com/cardiology/generalcardiology/118042
Author :
Publish date : 2025-10-20 19:21:00
Copyright for syndicated content belongs to the linked Source.
